Globus Medical Q2 FY26 GAAP diluted EPS drops 26.2% to $1.10; net sales rise 5.9% to $789.6 million - GMED News | RalliesGlobus Medical Q2 FY26 GAAP diluted EPS drops 26.2% to $1.10; net sales rise 5.9% to $789.6 million
G
GMED• Q2 results and full-year outlook
- Globus Medical Q2 GAAP diluted EPS fell 26.2% to USD 1.10 as net sales rose 5.9% to USD 789.6 million.
- GAAP net income dropped 25.3% to USD 151.6 million, primarily due to the prior-year Nevro bargain purchase gain.
- Non-GAAP diluted EPS more than doubled to USD 1.34; management cited broad-based share gains, led by US Spine growth.
- Full-year revenue guidance was reaffirmed at USD 3.18 billion-USD 3.22 billion; non-GAAP EPS outlook was raised to USD 4.95-USD 5.05.
•
